Trials / Completed
CompletedNCT00260065
A Study of Decitabine Given to Adults With Advanced-Stage Myelodysplastic Syndromes
A Phase 2 Study of Decitabine Administered Daily for 5 Days Every 4 Weeks to Adults With Advanced-Stage Myelodysplastic Syndromes
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 99 (actual)
- Sponsor
- Eisai Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine the overall response rate in patients with myelodysplastic syndromes (MDS) given a daily dosing schedule of decitabine.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Decitabine | 20mg/m\^2, IV on days 1-5 of each 28 day cycle; until progression, death or unacceptable toxicity develops. |
Timeline
- Start date
- 2005-05-01
- Primary completion
- 2008-06-01
- Completion
- 2008-12-01
- First posted
- 2005-12-01
- Last updated
- 2013-05-20
- Results posted
- 2009-09-04
Locations
21 sites across 2 countries: United States, Canada
Source: ClinicalTrials.gov record NCT00260065. Inclusion in this directory is not an endorsement.